Cervavac

The Serum Institute of India's (SII) quadrivalent human papillomavirus (qHPV) vaccine 'CERVAVAC' will be available in the private market this month, news agency PTI reported, quoting official sources. CERVAVAC is a cervical cancer vaccine developed by SII, a Pune-based pharmaceutical firm. It is India's first indigenously developed qHPV vaccine. Each vial of CERVAVAC will be priced at Rs 2,000. Two doses can be administered using one vial. Serum Institute's HPV vaccine against cervical cancer CERVAVAC to be available in pvt market this month. The first indigenously-developed HPV vaccine will be priced at Rs 2,000 per vial of two doses: Official sources— Press Trust of India (@PTI_News) SII launched CERVAVAC on January 24, 2023, on the occasion of National Girl Child’s Day. In India, the second most frequent cancer among women aged 15 to 44 years is cervical cancer. Most cervical cancers are caused by the human papillomavirus, and are sexually transmitted. CERVAVAC has demonstrated a robust antibody response against all targeted HPV types, and in all dose and age groups. The response is nearly 1,000 times higher than the baseline. The scientific completion of the vaccine was announced in September, 2022. What Are HPV Vaccines? HPV vaccines protect against infection caused by human papillomaviruses (HPV), which represent a group of more than 200 related viruses. Of these, more than 40 are spread through direct sexual contact. As many as two HPV types cause genital warts, and...

Pune-based pharmaceutical firm Serum Institute of India (SII) and the Department of Biotechnology (DBT) will launch India’s first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer on Thursday, September 1, 2022, media reports said. The qHPV vaccine is called CERVAVAC. Last month, the Drugs Controller General of India (DCGI) granted market authorisation to SII to manufacture an indigenously developed vaccine for the prevention of cervical cancer. In India, the second most frequent cancer among women aged 15 to 44 years is cervical cancer. Most cervical cancers are caused by the human papillomavirus, and are sexually transmitted. According to a report by news agency PTI, the vaccine will be launched by Union Minister of Science and Technology Jitendra Singh at India International Centre, Delhi. Adar Poonawalla, CEO of the SII, will also be present at the event. Vaccine Demonstrates Robust Antibody Response Against All Targeted HPV Types CERVAVAC has demonstrated a robust antibody response against all targeted HPV types, and in all dose and age groups. The response is nearly 1,000 times higher than the baseline. On June 15, 2022, the DCGI’s Subject Expert Committee (SEC) recommended the qHPV vaccine developed by the SII for cervical cancer patients belonging to the age group of nine to 26 years. Both male and female patients with cervical cancer belonging to this age group can receive the vaccine. Following the successful completi...

For the first time in India, a domestically-made vaccine that provides protection against cervical cancer—the second-most common type of cancer afflicting women in the country—will be accessible to the majority of the population, including the poorest, according to leading healthcare professionals. The vaccine, Cervavac, is produced by The Serum Institute of India (SII), the world’s largest vaccine manufacturer. The vaccine shot is expected to launch by December this year, SII chief executive Adar Poonawalla said in a statement Tuesday. “Cervavac will make India self-sufficient in controlling female mortality caused by cervical cancer. The government of India will induct it in the national [vaccination] program in a few months,” Poonawalla said. The vaccine protects against the Human Papilloma Virus, the main cause of cervical cancer and a potential cause of other cancers. SSI says it will be accessible to both men and women at a price range of 200 to 400 rupees—about $2.50 to $5. Dr. Smita Joshi, leader of the SII’s HPV vaccine study, said “The vaccine will be chiefly beneficial for girls aged 9 to 15 or women who are not yet sexually active. “If we vaccinate adolescent girls now, its effect on reducing the cancer burden in the country will be seen within three to four decades,” she said. According to Joshi, the effectiveness of the vaccine is lower among adult women, who will require cervical cancer screenings—preferably with an HPV test—followed by appropriate managemen...

Serum Institute of India's (SII's) Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer was launched in Delhi on Thursday, September 1. The qHPV vaccine, called CERVAVAC, is India's first indigenously developed vaccine against cervical cancer. Following the launch, Adar Poonawalla, the CEO of the SII, said the vaccine for the prevention of cervical cancer will be available in a few months, and may be priced between Rs 200 to Rs 400. However, he said the prices are yet to be finalised, news agency ANI reported. Delhi | The vaccine for cervical cancer will be available in a few months. Will give it to our country first & later to the world. May be priced between Rs 200-400 but prices yet to be finalized. Preparing to make 200 million doses in 2 years: Serum Institute CEO, Adar Poonawalla Poonawalla also said that CERVAVAC will be administered to people in India first, and later to the world. He stated that SII is preparing to make 200 million doses of the qHPV vaccine in two years. In July, the Drugs Controller General of India (DCGI) granted market authorisation to SII to manufacture an indigenously developed vaccine for the prevention of cervical cancer. In India, the second most frequent cancer among women aged 15 to 44 years is cervical cancer. Most cervical cancers are caused by the human papillomavirus, and are sexually transmitted. The vaccine was launched by Union Minister of Science and Technology Jitendra Singh at India International Centre, Del...

New Delhi: Cervical cancer is the fourth most prevalent cancer in women worldwide, despite being generally avoidable, according to the World Health Organisation (WHO). An estimated 570,00 women were diagnosed with the illness in 2018, and it was responsible for 311,000 fatalities worldwide. On Thursday, September 1, Dr. Jitendra Singh, Union Minister of Science and Technology, launched Cervavac, India's first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer. HPV is mainly transmitted through sexual contact and most people are infected with HPV shortly after the onset of sexual activity. More than 90% of them clear the infection eventually. Experts say that cervical cancer is curable if detected early and treated effectively. Cervical cancer can be prevented at a reasonable cost by receiving an HPV vaccine, getting screened for it, and treating pre-cancerous lesions. Here’s all you need to know about the causes, symptoms, and treatment of cervical cancer. What Is Cervical Cancer? According to the World Health Organization (WHO), a woman's cervix is where cervical cancer develops (the entrance to the uterus from the vagina). Human papillomaviruses (HPV), an incredibly prevalent virus spread through sexual contact, are associated with 99% of cervical cancer occurrences. Although the majority of HPV infections are self-limiting and symptomless, persistent infections can lead to cervical cancer in females. The fourth ...

The Centre plans to roll out India’s first Quadrivalent Human Papillomavirus vaccine (qHPV), manufactured by the Serum Institute of India (SII), against cervical cancer as part of the national immunization program by this year-end. Experts see this as a real opportunity to eliminate cervical cancer and have expressed the hope that it will be rolled out in national HPV vaccination strategies, and be available at a cost more affordable than existing vaccines. Cervical cancer is the second most common cancer type and the second most common cause of cancer death in women of reproductive age (15–44). India accounts for about a fifth of the global burden, with 1.23 lakh cases and around 67,000 deaths per year according to the World Health Organization’s International Agency for Research on Cancer (IARC-WHO). The Drug Controller General of India (DGCI), which had allowed the company to start manufacturing the vaccine on July 6, recommended market authorization to SII on July 12. The drug controller based its approval following a recommendation by the Subject Expert Committee (SEC) on Covid-19 on June 15. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Most sexually active women and men will be infected at some point in their lives, and some may be repeatedly infected. Cervical cancer is by far the most common HPV-related disease. A majority of this type of cancer – more than 95 % is caused because of HPV. Immunization with the HPV vaccine ...

Context: Cervavac, India’s first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer has been developed. About the new vaccine • Cervavac was developed by the Pune-based Serum Institute of India in coordination with the Government of India’s Department of Biotechnology (DBT). • HPV vaccines are given in two doses and the antibodies that develop after both are administered can last up to six or seven years. • Unlike Covid vaccines, booster shots may not be required for the cervical cancer vaccine. • Until now, the HPV vaccines available in India were produced by foreign manufacturers at an approximate cost of Rs 2,000 to Rs 3,500 per dose. • Cervavac is likely to be significantly cheaper, slated to cost approximately Rs. 200 to 400. • It has also demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups. How common is cervical cancer in India? • Despite being largely preventable, cervical cancer is the fourth most common cancer among women globally, according to the WHO. • Current estimates indicate that every year approximately 25 lakhs women are diagnosed with cervical cancer, and over 75 thousand dies from the disease in India, and 83 % of invasive cervical cancers are attributed to HPVs 16 or 18 in India, and 70% of cases worldwide. • India accounts for about a fifth of the global burden of cervical cancer, with 1.23 l...

From UPSC perspective, the following things are important : Prelims level : Cervavac, Cervical cancer Mains level : Menstrual hygiene and related diseases Union Minister of Science and Technology has announced the scientific completion of Cervavac, India’s first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for the prevention of cervical cancer. What is Cervavac? • Cervavac was developed by the Pune-based Serum Institute of India in coordination with the Department of Biotechnology (DBT). • The project to develop the vaccine was implemented by the then secretary of the DBT, Dr. M K Bhan in 2011. • Since then, 30 meetings of scientific advisory groups and site visits conducted by DBT have helped review the scientific merit of the entire journey to develop the vaccine. • Cervavac received market authorisation approval from the Drug Controller General of India on July 12 this year. What is so unique about Cervavac? • HPV vaccines are given in two doses and data has shown that the antibodies that develop after both are administered can last up to six or seven years. • Unlike Covid vaccines, booster shots may not be required for the cervical cancer vaccine. • Until now, the HPV vaccines available in India were produced by foreign manufacturers at an approximate cost of Rs 2,000 to Rs 3,500 per dose. • Cervavac is likely to be significantly cheaper, slated to cost approximately Rs 200 to 400. • It has also demonstrated a robust antibody response that is...